ES2196361T3 - Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr. - Google Patents

Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.

Info

Publication number
ES2196361T3
ES2196361T3 ES97939631T ES97939631T ES2196361T3 ES 2196361 T3 ES2196361 T3 ES 2196361T3 ES 97939631 T ES97939631 T ES 97939631T ES 97939631 T ES97939631 T ES 97939631T ES 2196361 T3 ES2196361 T3 ES 2196361T3
Authority
ES
Spain
Prior art keywords
rar
therapeutic combinations
rar antagonists
rxr agonists
rxr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97939631T
Other languages
English (en)
Spanish (es)
Inventor
Pierre Chambon
Hinrich Gronemeyer
Peter R Dept Reczek
Jacek Dept Ostrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Bristol Myers Squibb Co
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Strasbourg, Bristol Myers Squibb Co filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2196361T3 publication Critical patent/ES2196361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
ES97939631T 1996-08-28 1997-08-28 Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr. Expired - Lifetime ES2196361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28

Publications (1)

Publication Number Publication Date
ES2196361T3 true ES2196361T3 (es) 2003-12-16

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97939631T Expired - Lifetime ES2196361T3 (es) 1996-08-28 1997-08-28 Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.

Country Status (11)

Country Link
US (2) US6130230A (enExample)
EP (1) EP0928200B1 (enExample)
JP (1) JP2001500486A (enExample)
AT (1) ATE236654T1 (enExample)
AU (1) AU731060B2 (enExample)
CA (1) CA2263817A1 (enExample)
DE (1) DE69720745T2 (enExample)
ES (1) ES2196361T3 (enExample)
IL (1) IL128723A0 (enExample)
NO (1) NO990912L (enExample)
WO (1) WO1998008546A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914465A (pt) 1998-09-29 2001-10-09 Gamida Cell Ltd Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
AU784377B2 (en) * 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis
AU4866201A (en) * 2000-04-13 2001-10-30 Pierre Chambon Compositions and methods for use in modulating immune system function
CA2410480A1 (en) 2000-05-26 2001-12-06 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
WO2002022113A2 (en) 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
JP2005500027A (ja) * 2001-06-11 2005-01-06 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ドーパミン分泌細胞の生存を増加させる方法
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
EP2329817A1 (en) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer
EP2723347B1 (en) 2011-06-24 2019-09-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
JP6348848B2 (ja) 2012-02-13 2018-06-27 ガミダ セル リミテッド 間葉系幹細胞の増殖
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
PL3380086T3 (pl) 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
WO2017214575A1 (en) * 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2019014492A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER
KR20200044889A (ko) 2017-08-31 2020-04-29 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575528A4 (en) 1991-03-18 1994-09-14 Salk Inst For Biological Studi Response element compositions and assays employing same
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
CA2140354A1 (en) * 1993-05-18 1994-11-24 Pierre Chambon Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor proteins
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
AU4530496A (en) 1995-01-13 1996-07-31 Salk Institute For Biological Studies, The Allosteric control of nuclear hormone receptors
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US6586455B1 (en) 1996-12-31 2003-07-01 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
JP2001507706A (ja) 1996-12-31 2001-06-12 ザ ソールク インスチチュート フォア バイオロジカル スタディズ Ｐｐａｒ―ガンマ活性化物質を使用する新生細胞増殖の結果である疾病状態の処置及びこの処置に有用な組成物
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Also Published As

Publication number Publication date
US6130230A (en) 2000-10-10
WO1998008546A3 (en) 1998-04-23
AU731060B2 (en) 2001-03-22
NO990912L (no) 1999-04-27
AU4167497A (en) 1998-03-19
WO1998008546A2 (en) 1998-03-05
JP2001500486A (ja) 2001-01-16
DE69720745T2 (de) 2004-02-26
NO990912D0 (no) 1999-02-25
ATE236654T1 (de) 2003-04-15
US6653322B1 (en) 2003-11-25
DE69720745D1 (de) 2003-05-15
EP0928200A2 (en) 1999-07-14
CA2263817A1 (en) 1998-03-05
EP0928200B1 (en) 2003-04-09
WO1998008546A8 (en) 2001-04-19
IL128723A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
DE60235775D1 (de) Intraluminale Vorrichtung mit einer therapeutisches-mittel enthaltenden Beschichtung
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ES2154277T3 (es) Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
ES2194050T3 (es) Uso de bisfosfonatos para inhibir la resorcion osea tras la implantacion de una protesis osea.
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
CU23226B7 (es) COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ATE413177T1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
HUP0401634A2 (hu) LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására
ES2185310T3 (es) Agente antivirico herbario.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
JPS6483024A (en) Cataplasm for cold
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
GB9827121D0 (en) Agent for lowering endothelin levels